Related Experiment Video
Updated: Dec 11, 2025
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.2K
Current therapies for malignant pleural mesothelioma
1Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan. t-nakano@hyo-med.ac.jp
Environmental Health and Preventive Medicine
|July 2, 2009
Summary
Malignant pleural mesothelioma treatment has advanced with pemetrexed and cisplatin chemotherapy, improving survival and antitumor activity. This combination shows significant response rates, especially in epithelioid subtypes.
Area of Science:
- Oncology
- Medical Research
Background:
- Mesothelioma is a lethal cancer linked to asbestos exposure.
- Current treatments offer limited efficacy.
Purpose of the Study:
- To evaluate the efficacy of novel chemotherapeutic regimens for malignant pleural mesothelioma.
- To assess the impact of pemetrexed-cisplatin combination therapy.
Main Methods:
- Phase III clinical trial comparing pemetrexed-cisplatin with cisplatin alone.
- Analysis of response rates, survival time, and antitumor activity.
Main Results:
- Pemetrexed-cisplatin significantly improved survival and antitumor activity versus cisplatin alone.
- The combination achieved approximately 50% response rate in epithelioid mesothelioma.
- Other combinations like gemcitabine-cisplatin also show promise.
Conclusions:
- Pemetrexed-cisplatin chemotherapy has transformed mesothelioma treatment perceptions.
- Prognosis is influenced by clinical factors and histological subtype.
- Combined modality treatments, including trimodality therapy, show therapeutic potential.
